Ryzumvi approval for adult presbyopia expands the approved uses of Viatris’s eye drug, the company announced on October 16, 2026. The U.S. Food and Drug Administration decision adds age-related difficulty focusing on nearby objects to the product’s existing indication, while Viatris explores a potential U.S. commercialization partner for the new use.
Key Takeaways
- The FDA approved Ryzumvi for presbyopia in adults, adding to its existing indication.
- Viatris holds exclusive U.S. commercialization rights under a licensing agreement with Opus Genetics.
- The company is exploring a commercialization partner; no completed agreement was announced.
Table of Contents
- Ryzumvi approval adds a distinct use
- U.S. commercialization remains the next business step
- Safety information accompanies the expanded indication
- Conclusion
Ryzumvi approval adds a distinct use
Viatris’s October 16 approval announcement identifies Ryzumvi as phentolamine ophthalmic solution 0.75%. The drug was already approved in the United States for pharmacologically induced mydriasis, or pupil dilation caused by medicines.
The new indication addresses presbyopia, the gradual loss of near-focusing ability associated with aging. Viatris says the condition typically becomes noticeable in the early to mid-40s and can cause eye strain and blurred near vision, affecting everyday tasks.
The distinction between the two indications matters: Viatris describes Ryzumvi as the only commercially available FDA-approved product for pharmacologically induced mydriasis, not as the only FDA-approved treatment for presbyopia.
| Item | Details |
|---|---|
| Announcement date | October 16, 2026 |
| Newly approved population | Adults with presbyopia |
| Existing mydriasis indication | Adults and pediatric patients aged 3 years and older |
| Formulation | Phentolamine ophthalmic solution 0.75% |
U.S. commercialization remains the next business step
Opus Genetics and Viatris, through an affiliated entity, have a global licensing agreement covering development of phentolamine ophthalmic solution 0.75%. That agreement grants Viatris exclusive rights to commercialize the product in the United States.
Viatris said it is exploring the potential for a U.S. partner to commercialize Ryzumvi for presbyopia. The announcement did not identify a selected partner, disclose partnership terms or provide a launch date for the new indication.
The regulatory decision therefore broadens the product’s approved scope, but it is separate from a completed commercialization arrangement. Viatris did not provide a revenue forecast for the new use.
Safety information accompanies the expanded indication
For presbyopia, the most common ocular adverse reactions reported in more than 5% of subjects were conjunctival hyperemia, or eye redness, at 21%, and instillation-site irritation at 16%.
The product’s safety information says it is not recommended for patients with active ocular inflammation. Contact-lens wearers should remove their lenses before administration and wait 10 minutes after dosing before reinserting them.
Conclusion
The approval expands Ryzumvi’s permitted uses, while the commercial plan for presbyopia remains under development. The next business development to watch is the outcome of Viatris’s stated exploration of a U.S. commercialization partner.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
